Arbor's hospital portfolio grows as Eisai sheds US rights to Gliadel
This article was originally published in Scrip
Eisai is continuing to rationalize operations and hone its focus on major products against a background of revenue pressures, this time through an agreement to divest to Arbor Pharmaceuticals the US rights to Gliadel Wafer (polifeprosan 20 with carmustine implant).
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?